Bridge Bio Pharma, Inc. BBIO
We take great care to ensure that the data presented and summarized in this overview for BridgeBio Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BBIO
View all-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$726 Million40.56% of portfolio
-
Viking Global Investors LP25.1MShares$587 Million2.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$309 Million0.01% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$245 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$142 Million64.21% of portfolio
-
State Street Corp Boston, MA5.39MShares$126 Million0.01% of portfolio
-
Laurion Capital Management LP New York, NY5.18MShares$121 Million1.4% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.42MShares$79.9 Million5.54% of portfolio
-
Janus Henderson Group PLC London, X03.31MShares$77.5 Million0.06% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.2MShares$74.9 Million5.7% of portfolio
Latest Institutional Activity in BBIO
Top Purchases
Top Sells
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Insider Transactions at BBIO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 04
2024
|
Randal W. Scott |
SELL
Open market or private sale
|
Indirect |
1,500
-27.27%
|
$46,500
$31.3 P/Share
|
Jun 03
2024
|
Randal W. Scott |
SELL
Open market or private sale
|
Indirect |
1,000
-7.91%
|
$29,000
$29.08 P/Share
|
May 16
2024
|
Neil Kumar CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
30,748
-0.62%
|
$953,188
$31.04 P/Share
|
May 16
2024
|
Neil Kumar CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
60,667
+1.22%
|
-
|
May 16
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,943
-15.42%
|
$432,233
$31.04 P/Share
|
May 16
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,507
+23.33%
|
-
|
Mar 01
2024
|
Randal W. Scott |
SELL
Open market or private sale
|
Indirect |
2,500
-27.78%
|
$85,000
$34.0 P/Share
|
Feb 16
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,919
-23.12%
|
$700,003
$37.21 P/Share
|
Feb 16
2024
|
Brian C Stephenson Secretary, Treasurer & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,996
+35.48%
|
-
|
Feb 16
2024
|
Neil Kumar CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
47,922
-0.97%
|
$1,773,114
$37.21 P/Share
|
Feb 16
2024
|
Neil Kumar CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
102,249
+2.04%
|
-
|
Feb 16
2024
|
Charles J Homcy |
SELL
Payment of exercise price or tax liability
|
Direct |
1,509
-0.12%
|
$55,833
$37.21 P/Share
|
Feb 16
2024
|
Charles J Homcy |
BUY
Exercise of conversion of derivative security
|
Direct |
3,760
+0.3%
|
-
|
Feb 15
2024
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
2,915
-62.3%
|
$107,855
$37.75 P/Share
|
Feb 15
2024
|
Hannah Valantine |
BUY
Exercise of conversion of derivative security
|
Direct |
2,915
+38.39%
|
$23,320
$8.45 P/Share
|
Jan 16
2024
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
2,915
-62.3%
|
$107,855
$37.97 P/Share
|
Jan 16
2024
|
Hannah Valantine |
BUY
Exercise of conversion of derivative security
|
Direct |
2,915
+38.39%
|
$23,320
$8.45 P/Share
|
Dec 26
2023
|
Frank Mccormick |
SELL
Open market or private sale
|
Indirect |
100,000
-13.74%
|
$4,200,000
$42.06 P/Share
|
Dec 18
2023
|
Randal W. Scott |
SELL
Open market or private sale
|
Indirect |
2,000
-18.18%
|
$80,000
$40.0 P/Share
|
Dec 15
2023
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
2,915
-62.3%
|
$104,940
$36.12 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 553K shares |
---|
Open market or private sale | 1.77M shares |
---|---|
Payment of exercise price or tax liability | 262K shares |